Name | FGF-401 |
---|---|
Synonyms |
1,8-Naphthyridine-1(2H)-carboxamide, N-[5-cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-
N-{5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl}-7-formyl-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide FGF401 |
Description | FGF-401 is an inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC50 of 1.9 nM. |
---|---|
Related Catalog | |
Target |
FGFR4:1.9 nM (IC50) |
In Vivo | FGF-401 is a FGFR4 inhibitor developed for the treatment of solid tumor. FGF-401 is a FGFR4 inhibitor in phase I/II clinical studies for the treatment of positive FGFR4 and KLB expresion solid tumors and hepatocellular carcinoma[1]. |
References |
[1]. WO2015059668A1 |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 852.1±65.0 °C at 760 mmHg |
Molecular Formula | C25H30N8O4 |
Molecular Weight | 506.557 |
Flash Point | 469.1±34.3 °C |
Exact Mass | 506.239014 |
LogP | -0.15 |
Vapour Pressure | 0.0±3.2 mmHg at 25°C |
Index of Refraction | 1.654 |
Storage condition | -20℃ |